Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Device Deals Update, January 2014

Executive Summary

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced December 2013-January 2014.

You may also be interested in...



German HTA Negative On Benefits Of First Ever Peanut Allergy Treatment

The decision by IQWiG could have an impact on how Palforzia is priced if the findings are upheld.

Lupin Expects Exeltis Partnership To Boost Solosec

Lupin is hoping that a newly-struck partnership with women’s health specialist Exeltis will improve the fortunes of its Solosec (secnidazole) bacterial vaginosis and trichomoniasis treatment in the US.

No OTC Sildenafil In Germany After Committee Rejects All Rx-To-OTC Switches

The German Expert Committee for Prescription has rejected the Rx-to-OTC reclassifications of sildenafil (50mg) for oral use and xylometazoline and ipratropium bromide for intranasal use. 

Topics

Related Companies

UsernamePublicRestriction

Register

MT035715

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel